KDC-MN-008 – Kodiac biolabs

Plain-language summaryIntrigue 90 / 100

MOTS-c is a 16-amino-acid peptide encoded inside mitochondrial DNA, making it a unique mitochondrial-derived peptide. It activates AMPK, a master metabolic regulator linked to insulin sensitivity, fat oxidation, and exercise capacity. Research interest spans metabolic disease and longevity. Stocked in the Kodiac catalog as a research-only powder for laboratory work; not a medicine, not for human consumption.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNovel, promising

66/100

First mitochondrial sORF peptide with real AMPK signal and maturing multi-lab preclinical base

Look, when the Lee and Cohen groups at USC published the MOTS-c discovery in 2015, the finding was legitimately surprising. A peptide encoded within the mitochondrial 12S rRNA gene, translated from a short open reading frame on the complementary strand. That’s not how people thought about mitochondrial genetics at the time. The mitochondrial genome was supposed to encode a handful of respiratory chain components plus the rRNA and tRNA scaffolding. Finding a biologically active peptide signal hiding in there was the kind of result that reshapes how investigators think about what mitochondria actually are.

The mechanism is what keeps us interested. MOTS-c activates AMPK, which is a well-worn pathway. But the way it does it, and the upstream biology, is not the typical story. The compound also modulates the methionine and folate cycles, which puts it at an interesting intersection between one-carbon metabolism and energy sensing. Multi-target in a way that opens genuine research questions rather than just adding complexity. The age-related decline in plasma MOTS-c levels in humans provides a rationale for the geroprotective angle thats hard to dismiss, even if it’s correlative.

Preclinical replication is real. This isnt a one-lab story. Multiple independent groups have extended the original USC work into diet-induced obesity models, exercise capacity, bone density, immune function, and aging contexts. For a 2015 discovery, the literature has grown at a solid pace. CohBar, the company that licensed the platform, has moved into Phase 1, which is further along the clinical pipeline than most peptides in this class ever get.

What we don’t love: the human data is essentially not there yet. Plasma-level correlations with aging are suggestive, not mechanistic. Phase 1 tells you almost nothing about efficacy. Until we see Phase 2 data in a real metabolic indication, the translational signal is more promise than proof. The preclinical effect sizes are real, but rodent-to-human translation in metabolic peptides has a well-documented failure rate.

We think the bench value here is high for anyone working on aging biology, mitochondrial signaling, or AMPK pathway research. MOTS-c gives you a clean way to probe mitochondrial-nuclear crosstalk in a way that simple AMPK activators don’t approximate. It’s also the most characterized member of a peptide family where the class-level biology is still being written. That’s useful. If you’re building a research program around metabolic aging or mitochondrial endocrinology, this compound belongs in the toolkit at the preclinical stage.

Novelty: 72
Mechanism promise: 76
In-category differentiation: 72
Evidence quality: 55
Translational signal: 42
Research bench value: 72

Rationale MOTS-c scores on novelty and mechanism because it’s the first characterized sORF peptide from the mitochondrial genome, opening a genuinely new class of endocrine signals. Evidence quality and translational signal are held back by the absence of completed human trials; Phase 1 is initiated by CohBar but no results are published, and the human signal so far is correlative (age-related plasma decline). Bench value is real for investigators working on aging, AMPK biology, or mitochondrial-nuclear crosstalk.

16-residue mitochondrial-derived peptide, AMPK pathway modulator

A short open reading frame encoded within mitochondrial 12S rRNA, reported to modulate insulin sensitivity, exercise capacity, and metabolic homeostasis through AMPK-dependent mechanisms.

Abstract

MOTS-c (Mitochondrial Open reading frame of the Twelve S rRNA-c; sequence Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg; CAS 1627580-64-6; molecular formula C100H152N28O22S2; molecular weight 2174.59) is a 16-amino-acid peptide encoded within an open reading frame in the mitochondrial 12S ribosomal RNA gene MT-RNR1, first characterized in 2015 by Changhan Lee, Pinchas Cohen, and colleagues at the University of Southern California. It is the first short open reading frame (sORF) peptide identified in the mitochondrial genome, and its discovery has opened a substantial line of work on small mitochondrial-encoded peptides as endocrine and paracrine signals. Reported activities include enhanced insulin sensitivity in diet-induced and genetic obesity models, increased exercise capacity, improved glucose homeostasis through AMP-activated protein kinase (AMPK) activation, attenuated age-related insulin resistance, and effects on bone mineral density and immune function. Plasma MOTS-c levels decline with age in humans, which is the rationale for the geroprotective framing of the compound in research-grade vendor literature. The published preclinical literature is robust and has expanded steadily since 2015 with multiple independent laboratories contributing replication and extension studies. There is no FDA-approved IND for MOTS-c in any indication; preliminary Phase 1 work has been initiated by CohBar, Inc., the company that has licensed the platform from USC. The compound is not approved by any regulatory authority for human or veterinary use.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-008Open in new tab →

Download PDF →

Acquire MOTS-c from the catalog

View MOTS-c →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: KDC-MN-008

MOTS-c

Abstract

Read the full monograph